49 results about "Tumor site" patented technology

This invention discloses a method for preparing a core-shell microneedle patch loaded with dual nanoparticles, comprising: preparing silica nanoparticles loaded with oxyhemoglobin and dihydroporphyrin e6; preparing calcium carbonate nanoparticles loaded with aPD-1 antibody; dispersing the silica nanoparticles loaded with oxyhemoglobin and dihydroporphyrin e6 in a polyvinyl alcohol solution to prepare the shell structure of the microneedles; preparing a polymer hydrogel; dispersing the calcium carbonate nanoparticles loaded with aPD-1 antibody in the polymer hydrogel to prepare the core structure of the microneedles; and casting the polyvinyl alcohol solution onto the backing of the microneedles to finally obtain the core-shell microneedle patch loaded with dual nanoparticles. The core-shell microneedle patch loaded with dual nanoparticles prepared by this invention can deliver nanoparticles to the tumor site, where the nanoparticles respond to the tumor microenvironment and activate the body's own immune system, thereby achieving a therapeutic effect on tumors.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

The application discloses a kind of sustainable oxygen production sonodynamic therapy nanoparticles, including core-shell structure, the core of core-shell structure is located in shell inside, the core of core-shell structure is manganese oxide nanoparticle, the shell of core-shell structure is the high molecular polymer of carrying sound sensitizer, manganese dioxide nanoparticle is manganese dioxide nanoparticle, sound sensitizer is one of porphyrin and its derivatives, high molecular polymer is polylactic acid glycolic acid copolymer, this kind of sustainable oxygen production sonodynamic therapy nanoparticles by using high molecular polymer simultaneously carrying manganese dioxide nanoparticle and sound sensitizer to enhance SDT effect, high molecular polymer has good biocompatibility and drug controlled release performance, not only can reduce the toxicity of manganese dioxide to normal tissue, can also make it continuously controllable with tumor site excess H2O2 Reaction generates oxygen, reverses tumor hypoxic microenvironment while providing sufficient oxygen for SDT, under the action of ultrasound, generate a large amount of ROS to inhibit tumor.

An arylboron compound, its preparation method, applications, and pharmaceutical compositions are disclosed for tumor imaging. The compound of formula (I) exhibits high fluorescence quantum efficiency through intramolecular charge transfer. The compound of formula (I) synthesized in this invention can be linked to different antibodies via Q3 at certain concentrations, allowing for precise targeting of corresponding tumors based on the antibody. This type of boron drug formulation can be used in boron neutron capture therapy to kill tumor cells. It exhibits better killing effects; the compound of formula (I) targets tumor cells through antigen-antibody interaction. After the boron-10-containing drug accumulates at the tumor site, neutron radiation triggers a nuclear reaction releasing alpha particles and... 7 Lithium particles kill cells; the range of these two particles is approximately 10 μm. High-energy-density heavy ions disrupt the DNA double helix structure in tumor cells, causing irreparable cell death. Simultaneously, the 10 μm distance avoids damage to normal cells and tissues.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

The application relates to the field of biological medicine, and discloses an active oxygen response thione aldehyde linker as well as a preparation method and application thereof. The thione aldehyde linker structure is a thione aldehyde structure with a p-hydroxyphenyl as a center. The thione aldehyde carbon atom is connected with two -CH2CH2COOH groups through a sulfur atom. The preparation method of the active oxygen response thione aldehyde linker comprises the following steps: dissolving 3-mercapto propionic acid and p-hydroxybenzaldehyde in ethyl acetate, adding trifluoroacetic acid as a catalyst, stirring and reacting at room temperature, and after the reaction is completed, the thione aldehyde linker is obtained through separation and purification. The thione aldehyde linker can respond to the increased ROS level in a tumor microenvironment, is broken under a high ROS condition, and thus realizes the release of a drug molecule connected therewith, which is beneficial to realizing the specific release of the drug at a tumor site.

The application of poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers in constructing micro / nanocarriers for antitumor drugs belongs to the field of biomedical polymer materials and nanomedicine. The antitumor drugs are small-molecule chemotherapeutic agents, small-molecule photosensitizers, small-molecule immunotherapeutic agents, and small-molecule radiosensitizers. The particle size of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 10–5000 nm. The effective concentration of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 1–500 mg / kg. The antitumor mechanism of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers includes increasing the activity of effector T cells in the tumor microenvironment and increasing the concentration of cytokines such as IFN-γ at the tumor site. In the field of tumor therapy, PLA and PLGA materials composed of D-lactic acid have shown good effects in inhibiting tumor growth, prolonging the survival period of tumor-bearing mice, and activating antitumor immune responses.

Provided herein are novel anti-CD20x anti-CD28 antibodies and methods of using such antibodies to treat B cell malignancies. The subject anti-CD20x anti-CD28 antibodies are capable of agonically binding to a CD28 costimulatory molecule on a T cell and to CD20 on a tumor cell. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in the treatment of B-cell malignancies in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies).

The application discloses a preparation method of a novel hierarchical drug release lemon exosome nano preparation and application thereof in brain glioma treatment and belongs to the field of nano medicines. The method comprises the following steps: extracting and purifying lemon exosomes, introducing an anti-glioma drug and a first part of LRP1 up-regulating agent into the inner cavity of the exosomes through electroporation, instantaneously constructing a tumor microenvironment responsive nanogel core to fix the drug, embedding a second part of LRP1 up-regulating agent into the lipid layer of the exosome, modifying Angiopep-2 to realize brain targeting, and obtaining the nano preparation through purification. The preparation has the hierarchical drug release characteristics of outer layer early release and inner cavity delayed release, can improve the efficiency of drug crossing the blood-brain barrier and accumulation at the tumor site, enhance the anti-glioma effect, solves the technical problem that the existing drug loading system is difficult to realize multi-drug phased release, and provides a new strategy for brain glioma treatment.

The application discloses a ROS / GSH responsive hyperbranched zwitterionic micelle and a preparation method and application thereof, and relates to a drug delivery system, ROS responsive zwitterionic micelles and GSH responsive zwitterionic micelles are prepared respectively, the ROS responsive zwitterionic micelles are loaded with anti-angiogenic drugs, and the GSH responsive zwitterionic micelles are loaded with anti-tumor stem cell drugs, so that the combined treatment of blood vessel normalization and tumor stem cell killing is realized, while the blood vessel normalization is realized, the restriction of the small intercellular gap of vascular endothelial cells caused by the blood vessel normalization on the enrichment and penetration of subsequent nano drugs in tumor sites is effectively solved, and the change of the interstitial pressure of tumor tissue caused by the blood vessel normalization is fully utilized to promote the deep penetration of small-size GSH responsive zwitterionic micelles into the internal region of the tumor, so that the killing of tumor stem cells is completed, and the combined treatment of the blood vessel normalization therapy and the tumor stem cell therapy is effectively realized.

This invention relates to an organic nanoparticle, its preparation method, and its application. The organic nanoparticle is 4SBZ-F NPs, 6SBZ-F NPs, 4STP-F NPs, or 6STP-F NPs. The organic nanoparticles of this invention exhibit excellent NIR-II fluorescence brightness, good biocompatibility, and significantly improved photostability compared to the commercial dye ICG. They can be efficiently enriched at tumor sites through enhanced penetration and retention effects. High signal-to-noise ratio and high-resolution NIR-II fluorescence imaging of mouse blood vessels, lymph nodes, and tumors can be achieved under low-power laser and short exposure time conditions.

This invention discloses a nanomedicine and its application in the four-modal synergistic treatment of ER+ breast cancer, encompassing gas therapy, photothermal therapy, photodynamic therapy, and combined therapy, relating to the fields of biotechnology and new medicine. This nanomedicine uses an amphiphilic polymer as a carrier and organic compounds and photosensitizers as drug loading agents. Through the synergistic effects of four modes—photothermal, photodynamic, gas therapy, and combined therapy—it effectively inhibits the growth and metastasis of breast cancer cells. The amphiphilic polymer, based on PHHM-ADT, is modified with hydrogen sulfide gas as a donor, and its amphiphilicity allows for spontaneous assembly into nanoscale hollow, regular spheres. Utilizing the high permeability and retention effect (EPR effect) at the tumor site, it achieves efficient drug accumulation in tumor tissue. The prodrug PSF couples fulvestrant and pabuxiparin via disulfide bonds, and the photosensitizer IR808 integrates photothermal and photodynamic therapy. The synergistic effect of multiple mechanisms of action enhances the therapeutic effect.

The application discloses a kind of nucleic acid nano vesicles based on sulfonium copolymerization peptide and its preparation method and application.The vesicle is formed by the electrostatic self-assembly of a kind of sulfonium copolymerization peptide and polynucleotide, and is stable nano vesicle with hollow structure.The vesicle is different from conventional solid nanoparticles, and its unique hollow structure provides space for co-loading other therapeutic agents (such as enzymes, chemotherapeutic drugs).The application also provides a preparation method of the nano vesicle, and its application as a carrier for simultaneously loading nucleic acid drugs and other active ingredients for synergistic treatment.The nano vesicle has extraordinary long-term storage stability, and can deliver siRNA and catalase to tumor sites, block CD47 "don't eat me" signal through gene silencing, and enzymatically degrade immunosuppressive factor H2O2 in tumor microenvironment, thereby remodeling tumor immune microenvironment, efficiently activating macrophages, dendritic cells and T cells, and producing strong synergistic anti-tumor immune effect.

The application provides a multifunctional nano drug delivery system based on iron-doped MOF and a preparation method and application thereof. The system comprises: an Fe / MOF core loaded with a chemotherapeutic drug and an HO-1 inhibitor; a PDA coating layer coated on the surface of the Fe / MOF core for providing near-infrared light heat conversion capability and surface modification interface; and E3 aptamer covalently coupled on the PDA coating layer, constituting a synergistic nano platform with active targeting, pH / NIR dual-responsive drug release, chemical kinetics therapy, ferroptosis sensitization, photothermal therapy and immune regulation functions. The nano system can realize efficient accumulation at the tumor site through active targeting mediated by E3 aptamer, and controllably release drugs under an acidic microenvironment or near-infrared light. A new strategy for multi-mechanism synergistic treatment is provided to overcome the multiple drug resistance and immunosuppression of mCRPC, and has important clinical application prospects.

The present application relates to the technical field of biological medicine, in particular to a kind of nano-molecular probe with targeting and its preparation method and application.The plasmid of immune checkpoint corresponding receptor of stable expression tumor surface negative regulation molecule is synthesized in the present application, which is prepared into targeted nano-molecular probe with cell membrane nanocapsule of enhancing T cell activity ligand and being marked with fluorescence, and melanin nanosphere of simultaneously loading therapeutic drug.The targeted nano-molecular probe provided in the present application can be long-circulated in vivo, reduce the dosage and administration frequency of chemotherapeutic drug.It also has the advantages of improving the drug resistance of tumor site to therapeutic drug, targeting tumor DNA damage and significantly enhancing the infiltration and activation of immune cells in tumor site.

The application discloses a kind of photoactivation biotin-biological orthogonal prodrug system and its anti-tumor application.The system integrates biotin targeting ligand, photo-caged tetrazine (TZ) group into one molecule through connecting chain, and can release activated TZ under specific wavelength light, then, TZ and trans-cyclooctene (TCO) modified prodrug or probe occur biological orthogonal reaction, realize the accurate release of tumor site.The system has the functions of active targeting, light-controlled rapid release and diagnosis and treatment integration, and has high tumor inhibition rate, which is significantly better than traditional chemotherapy, and has no obvious systemic toxicity, providing a new strategy for precise treatment of malignant tumors.

This invention provides an activatable semiconductor polymer, its preparation method, and its applications. The activatable semiconductor polymer of this invention can efficiently accumulate at tumor sites. Due to the presence of electron-withdrawing groups on its side chains, the polymer's fluorescence is quenched. Upon response to tumor markers—biothiols, reactive oxygen species, and cathepsin B—the polymer's fluorescence recovers, enabling precise imaging and sonodynamic therapy at the tumor site. Simultaneously, the activatable semiconductor polymer of this invention can label immune cells (such as dendritic cells and macrophages) and track their metastasis from the tumor to the draining lymph nodes.

This invention relates to a nuclear-targeted multimodal imaging diagnostic probe with BNCT therapeutic efficacy, its preparation, and its application, belonging to the fields of biomedicine and nuclear medicine technology. This boron drug contains... 10 Using acetylacetone difluoroborate as the parent nucleus, this invention endows the tumor with nuclear targeting ability by introducing N- or S-containing heterocyclic structures, while utilizing its conjugated structure to provide fluorescence / photoacoustic dual-modal imaging functionality. Based on this, the invention achieves three core functions: first, through fluorescence / photoacoustic dual-modal imaging, it enables the visual localization and real-time monitoring of tumor sites; second, by leveraging the binding of nuclear targeting groups to nuclear DNA / RNA, it... 10 B is precisely delivered into the nucleus, significantly improving the killing efficiency of BNCT; thirdly, thermal neutron irradiation is performed under imaging guidance, triggering... 10 The B(n,α)⁷Li nuclear fission reaction ultimately enables high-precision integrated diagnosis and treatment. This invention also discloses a method for preparing this probe, which has promising clinical application prospects.

This application relates to a peptide targeting LGR5, a PET molecular probe, its preparation method, and its application. The peptide is any one of the following: (1) its amino acid sequence is YLASRVH; (2) a derived peptide formed by substituting one or more amino acids into the amino acid sequence shown in (1), wherein the derived peptide has the same or substantially the same function as the peptide with the sequence shown in (1); (3) a derived peptide after chemical or genetic modification of the peptide in (1) or (2). The PET molecular probe targeting LGR5 includes a peptide targeting LGR5, a chelating agent, and a radionuclide. The probe of the present invention has good stability, high affinity and specificity for LGR5, and can sensitively monitor the LGR5 expression level at the tumor site; it is also rapidly metabolized in vivo and provides fast imaging. In LGR5-positive tumor models, it can reach the tumor site in a short time and obtain high-contrast PET imaging effects.

The application relates to the technical field of biological medicine, and discloses a preparation method of a liposome with a pH response type membrane fusion effect and application of the liposome. The pyridium betaine-terminated lipid molecule provided by the application can be quickly and reversibly protonated in a weak acid microenvironment of a tumor, the surface charge of the liposome is changed from negative to positive, and the precise switch of the membrane fusion behavior is realized; the self-adaptive fusion liposome constructed based on the pyridium betaine-terminated lipid molecule successfully converts the non-specific toxicity risk of the traditional fusion liposome into a space-limited intelligent response, remains stable and inert in blood circulation (pH=7.4), and specifically activates the membrane fusion at a tumor site, realizes direct cytoplasmic delivery of a drug and avoids lysosome degradation; the STING nano agonist constructed by loading the nano composite of a STING pathway agonist and a divalent metal ion on the platform exhibits a strong pH-dependent anti-tumor immune activation effect in vitro and in vivo, and significantly inhibits tumor growth while the systemic toxicity is extremely low.

This invention belongs to the field of biomedical technology, specifically relating to a Pt 2+ - Carbon dot@protoporphyrin sonodynamic drug delivery system, its preparation method and application, by loading Pt onto the surface of carbon dots 2+ Modification layer, to obtain Pt 2+ After carbon dots are formed, protoporphyrin is loaded onto them to obtain a carbon dot core with Pt loaded on the carbon dot surface. 2+ Modification layer, in Pt 2+ A sonodynamic drug delivery system with a protoporphyrin-modified layer loaded on the outside of the modified layer can be used in anti-tumor drugs to screen liver cancer cells and normal cells. It has good biocompatibility and significant in vivo sonodynamic anti-tumor effects. It can promote the generation of reactive oxygen species, target and remain in the subcutaneous tumor site in vivo for a long time, increase the mortality rate of cancer cells, and inhibit tumor growth. In a 3D constructed in vitro hepatocellular tumor microenvironment model, this drug delivery system still has superior sonodynamic therapeutic effects.

The present application relates to the field of radiopharmaceutical chemistry and clinical nuclear medicine technology, and particularly relates to a neurotensin receptor subtype 1 (NTSR1) antagonist derivative and application thereof. A radioactive preparation obtained by labeling the NTSR1 antagonist derivative with a radionuclide is simple to prepare, has high radiochemical purity, good stability, high uptake in the tumor site of a tumor-bearing mouse and a high target-to-non-target ratio, and has specific binding with NTSR1 in the tumor, and is a novel tumor radioactive drug with promotional application value.

The invention relates to the technical field of synthetic biology and immunotherapy, in particular to an immune gene combination fragment responding to a tumor microenvironment, a recombinant plasmid, probiotics and application of the immune gene combination fragment, the recombinant plasmid and the probiotics. The preparation method comprises the following steps: selecting phytobacterium plantarum, casei casei, casei paracasei, streptococcus thermophilus and lactococcus lactis as a probiotic chassis, further designing and assembling an immune gene combination fragment of immune checkpoint inhibitors (PD-L1 and CTLA-4), and uploading the immune gene combination fragment to the bacterial strain to construct customized probiotics, so as to prepare the immune checkpoint inhibitors (PD-L1 and CTLA-4). The in-vitro expression condition is researched; it is found that in a mouse tumor model, the customized probiotics can release PD-L1 and CTLA-4 nano antibodies at the tumor site, the tumor microenvironment is reversed, the immune system is mobilized, and the anti-tumor effect is enhanced. The research is expected to provide a safe and efficient anti-tumor strategy for tumor treatment, and new hope is brought to tumor patients.

The present application relates to the technical field of biological materials, and particularly relates to in-situ programmed synthesis of quantum dots of cells and a preparation method and application thereof. The core innovation of the present application is that a multi-level nano-synthesizer with responsiveness is designed, and a bottleneck that functional nano-materials cannot be in-situ synthesized at the level of living bodies and cells is broken. The present application promotes the development of biological synthesis of nano-materials, especially in-situ programmed synthesis of quantum dots. After the unique nano-synthesizer of the present application is internalized by cells, a diselenide bond is cleaved by glutathione to generate active selenium species, then the silicon shell skeleton collapses, silver precursors are released, and quantum dots are generated by reaction with selenium precursors. The quantum dots provided by the present application can be in-situ synthesized at tumor sites, induce oxidative stress, combine with the photothermal effect of near-infrared quantum dots, and finally lead to tumor cell apoptosis or necrosis, effectively delaying the development of tumors in tumor-bearing mice and prolonging the survival period of the mice.

The present application relates to a kind of NAD (P) H response type diagnosis and treatment integrated boron medicine and its preparation method, the boron medicine with 10 B acetylacetone difluoroboric ester as mother nucleus, by introducing the cell nucleus target ability of N-containing or S-containing heterocyclic structure, simultaneously introduce the response unit that can specifically respond to high expression NAD (P) H in tumor microenvironment, activate fluorescence / photoacoustic dual-mode imaging signal, realize the visual positioning of tumor site.On this basis, the present application realizes three big core functions: one is through NAD (P) H response point light imaging, effectively reduce background signal interference;Two is by means of N or S atom and the combination of cell nucleus DNA / RNA, will 10 B be accurately delivered to nucleus, significantly improve BNCT killing efficiency;Three is under the guidance of imaging, thermal neutron irradiation is carried out, triggers 10 B (n, α) 7 Li nuclear fission reaction, finally realizes high-precision diagnosis and treatment integration.The preparation method of the boron medicine is also disclosed, can be used for preparing malignant tumor diagnosis and treatment drug, has good clinical application prospect.

This invention belongs to the field of biomedical technology and discloses a paclitaxel reduction-responsive prodrug micelle with high encapsulation efficiency and its preparation method. The paclitaxel-loaded reduction-responsive prodrug micelles prepared in this invention use biocompatible polyethylene glycol (mPEG) and the drug indomethacin (IND) as the hydrophilic and hydrophobic ends of the micelles, respectively, exhibiting synergistic antitumor effects. Simultaneously, it can reverse multidrug resistance to paclitaxel, increase the sensitivity of drug-resistant cells to paclitaxel, and introduce disulfide bonds between the hydrophilic and hydrophobic ends as a linker arm for reduction-sensitive response, responding to the high concentration of GSH in tumor cells to achieve targeted and precise drug release within tumor cells. This prodrug micelle achieves the goals of solubilizing poorly soluble drugs, tumor targeting, and precise drug release at tumor sites, thus enhancing drug efficacy.

This invention discloses a method for preparing and applying magnetically responsive gel microspheres for rapid drug release controlled by magnetothermal stimulation, belonging to the fields of biomedical materials and tumor treatment technology. The method includes: preparing magnetic beads conjugated with targeting antibodies and antitumor drugs; dispersing the magnetic beads and an immune environment modulator in a thermosensitive gel precursor solution containing poloxamer 407; and preparing gel microspheres with uniform particle size using microfluidic technology. The microspheres obtained by this invention possess magnetically induced targeting and thermosensitive properties. Under the action of an external alternating magnetic field, they can rapidly generate a magnetothermal effect, triggering the thermal melting and liquefaction of the gel microspheres at the tumor site, achieving on-demand, rapid, and controllable drug release, and simultaneously exerting a synergistic effect of magnetothermal killing and chemotherapy killing, suitable for the treatment of HER2-positive tumors.

This invention discloses a ternary nanoparticle, its preparation method, and its applications, relating to the field of biomedical technology. The invention constructs a carrier-free, fully active ternary nanoparticle (diPCL NPs). This nanoplatform connects PTX dimer (diPTX), celecoxib (CXB) dimer (diCXB), and lonidamine (LND) dimer (diLND) via disulfide bonds for chemoimmunotherapy of drug-resistant tumors. diPCL NPs accumulate at tumor sites through enhanced permeability and retention (EPR) effects and circulate continuously in the bloodstream. In the high GSH tumor microenvironment, disulfide bond cleavage releases the active drug, exerting chemotherapeutic, immune-activating, sensitizing, and metabolic-regulating effects. diPCL NPs exhibit high antitumor efficacy and good safety profile within the therapeutic window in both breast cancer and paclitaxel-resistant models.

The application discloses a biological macromolecular drug for tumor treatment, which has tissue protein adhesion, can continuously improve the oxidative stress environment of a tumor site by prolonging the time at the tumor site, can inhibit tumor growth by tumor microenvironment regulation, can also be used as an auxiliary therapeutic agent to enhance the curative effect of other tumor treatments, and has a good clinical transformation prospect.

A clofazimine-based pharmaceutical suspension and an application thereof, wherein a drug delivery system has near-infrared fluorescence, photoacoustic imaging effect and red dye characteristics for in vivo tracing, as well as a near-infrared photothermal effect for tumor treatment. The drug delivery system combines the near-infrared photothermal effect with the anti-tumor effect of the drug itself, and adopts a combination of phototherapy and traditional chemotherapy to achieve effective inhibition of tumor occurrence and development; in addition, by combining the near-infrared fluorescence effect and the photoacoustic effect, a multimodal combined tracing technique can be used to assist intraoperative lymph node dissection, and the drug can achieve long-term retention at the tumor site, overcoming the limitations of traditional imaging in "black box" environments of strong light or deep tissues, making it more suitable for intraoperative navigation; the system possesses good biosafety, high sensitivity, high tissue penetration and photostability, which can reduce the inconvenience of multiple clinical administrations and increase compliance.